We are live on ! Find out more
PPBT

Purple Biotech
PPBT

5 hedge funds and large institutions have $96K invested in Purple Biotech in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more capital invested

Capital invested by funds: $43K → $96K (+$53K)

0% more funds holding

Funds holding: 5 → 5 (0)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$29.2K
2
ASN
Advisory Services Network
Georgia
+$5.84K
3
VF
Virtu Financial
New York
+$5.84K
4
UBS Group
UBS Group
Switzerland
+$4.38K

Top Sellers

No sellers this quarter

PPBT Hedge Fund Activity: Q4 2019 in Review

5 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2019, worth a combined $96K — up 123% from $43K a quarter earlier.

Fund positioning in PPBT was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $29.2K.

  • 5 institutional investors held Purple Biotech (PPBT) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $96K of Purple Biotech stock for Q4 2019, up 123% quarter-over-quarter.
  • 0 funds opened new Purple Biotech positions in Q4 2019 and 0 closed out.
  • The largest Purple Biotech buyer in Q4 2019 was Morgan Stanley, an estimated $29.2K added.

Based on aggregated 13F filings for Q4 2019.